ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / DVA
FMS (57) SHC (49) PGNY (79) AGL (36) ⌘ Pro Terminal →

DaVita Inc. (DVA) — RQD Stock Rating Cockpit

$187.50 -3.01% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $186.93

DaVita Inc. (DVA) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (steady margins, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →
ROARABLE B • BUY Cap $11.79B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DVA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, DaVita Inc. (NYSE: DVA) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $187.50 (-3.01% 1D, market cap $11.79B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, DVA ranks #37 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DVA compare to FMS and SHC in the Health Care sector?
▼

Within the Health Care sector (Misc Health and Biotechnology Services), DVA carries a Roarable B (74/100 RQD), trailing P/E of 11.4x, gross margin of —, and ROIC of 29.2%. By comparison, FMS (Fresenius Medical Care AG American) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $12.55B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DVA?
▼

Per DVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000927066), DaVita Inc. generated $13.64B in revenue (+6.5% YoY), $1.08B in net income, and $1.31B in free cash flow against $17.48B in total assets and $7.34B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $186.94 (-0.30%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 9.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510074
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B-
Cash (15)Whales (13)SEC (12)Macro (16)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
$260 Bull$201 Base$154 Bear
📬 FREE DVA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DVA)Realized 20D OHLCV Swing Band: ±8.3%
Deterministic 5-Pillar Attribution (74/100 Composite)
🔍 WHY DVA SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime × Technicals: 59% of 52W Range • RSI-14 at 52.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk12/20 pts (-8 pt drag)

Balance-sheet & 10-K footnote risk deducts 8 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
66
Grade B-$180.70-2.2% Next Q
Q2 (-2Q)
69
Grade B-$176.81+4% Next Q
Q3 (-1Q)
71
Grade B$183.93+1.9% Next Q
Current
74
Grade B$187.50+7.3% Hist 90D α
Trajectory: B- (66) → B (74)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DVA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, DVA faces multiple-compression risk if 11.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($182.32) or 200D SMA ($178.31) invalidates the momentum regime and cuts Target Base ($201.00) toward Bear Floor ($153.75).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 74%NO 26%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
52.630 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
1.66>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE59% OF RANGE
L: $101$187.50H: $247
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (steady margins and healthy balance-sheet cushion).

Factor Grade: BRQD 15 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 31 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on DVA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (75)

29.2% ROIC with 42.0% gross margin and 10.63% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 1.66 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (78)

31/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like DVA
  • ✓Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (DVA Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.69%⚡ TESTING RESISTANCE
2026-11-03O $193.3H $193.3L $187.5C $187.5VOL 1.76M
RES: $194.9SUP: $171.0SMA50: $182.3SMA200: $178.3
$255.5$222.3$189.1$155.9$122.6RES $194.9SUP $171.0$187.52026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DVA Butterfly Map → + Track DVA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
1.5%/yr Implied 5Y Growth

vs. +6.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DVA)

Health Care Rank #37 of 1016 ⚔️ FMS vs DVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DVA vs. FMS, SHC, PGNY, AGL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DaVita Inc. (DVA) ranks #37 by composite RQD confidence (74/100, grade B) and #94 by equity capitalization ($11.79B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with DVA at 74/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DVA ACTIVE
DaVita Inc.
B 74/100 11.4x — 29.2% -3.01% $11.79B Benchmark Subject
FMS
Fresenius Medical Care AG American
D+ 57/100 32.8x — 9.9% -2.85% $12.55B /fms-vs-dva →
SHC
Sotera Health Company
D 49/100 68.5x 55.5% 3.1% -2.94% $5.18B /shc-vs-dva →
PGNY
Progyny Inc.
B+ 79/100 37.2x 23.6% 16.7% +2.78% $2.24B /pgny-vs-dva →
AGL
agilon health inc.
D- 36/100 — — -35.0% -1.21% $1.43B /agl-vs-dva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000927066

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DaVita Inc. (DVA) reported GAAP revenue of $13.64B (+6.5% vs. FY2024 revenue of $12.82B , and +12.4% cumulative change since FY2023) , GAAP net income of $1.08B, operating cash flow of $1.89B, and free cash flow of $1.31B (-10.6% YoY). On the balance sheet, DVA closed FY2025 with $17.48B in total assets against $7.34B in total debt (Altman Z-Score: 1.66, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $13.64B $1.08B $1.89B $1.31B $17.48B $7.34B
FY2024 (FY) 2024-12-31 $12.82B $1.25B $2.02B $1.47B $17.29B $6.84B
FY2023 (FY) 2023-12-31 $12.14B $957.0M $2.06B $1.51B $14.57B $3.41B

3. DVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, DaVita Inc. (NYSE: DVA) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $187.50 (-3.01% 1D, market cap $11.79B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, DVA ranks #37 in composite RQD confidence.

How does DVA compare to FMS and SHC in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), DVA carries a Roarable B (74/100 RQD), trailing P/E of 11.4x, gross margin of —, and ROIC of 29.2%. By comparison, FMS (Fresenius Medical Care AG American) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $12.55B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DVA?

Per DVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000927066), DaVita Inc. generated $13.64B in revenue (+6.5% YoY), $1.08B in net income, and $1.31B in free cash flow against $17.48B in total assets and $7.34B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DVA trading relative to its 50-day, 200-day, and 52-week technical levels?

DVA last traded at $187.50 (-3.01% on volume of 1,760,644 shares), positioning the stock +2.84% above its 50-day simple moving average ($182.32) and +5.15% above its 200-day simple moving average ($178.31). Across its 52-week range of $101.00 to $247.49, DVA sits at the 59.0% percentile with a 14-day RSI of 52.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($171.94 to $203.06).

DVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell DVA stock right now?

DaVita Inc. (DVA) currently earns a Roarable Rating of B (Buy — BUY) with 74/100 RQD Confidence. High-quality cash engine (steady margins, 29% return on capital) with steady institutional support.

What is DVA's 12-month price target and RQD AI Jury consensus?

DVA's 12-month base price target is $201 (range $153.75 to $259.86), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: DVA RQD Cockpit DVA 12M Forecast DVA Earnings & Move DVA Dividends & DRIP DVA Insiders & 13F DVA Whale Options DVA Profit Sankey DVA News & Why
ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DVA — DaVita Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:34Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DVA scores 77 out of 100, graded B+, with the verdict "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

  • Fundamental Cash Engine (15 / 20): Return on invested capital of 29.2% and a free cash flow yield of 10.63% indicate strong cash generation relative to capital and to the current market value. The upside driver is the cash return profile; the valuation tradeoff is that the score is not maximal, reflecting a mid-range rather than top-tier cash profile.
  • Whale 13F Flow (16 / 20): The rating reflects institutional accumulation and options positioning. For a prospective investor, this signals institutional interest, but the source data does not identify the specific holders or the size of positions (see Analyst View section).
  • Insider Conviction (18 / 20): This is the highest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow. Insider buying clustering is often read as management confidence, though the source data does not itemize the individual transactions.
  • Macro Regime Fit (16 / 20): With a beta of 0.95, DVA has been measured as slightly less volatile than the broader market, per the market data. Sector sensitivity is part of this pillar's basis; the source does not detail the macro factors.
  • Forensic Balance Sheet (12 / 20): The Altman Z-Score of 1.66 sits in a range that warrants attention, while the Piotroski F-Score of 8/9 indicates strong fundamental health signals. Debt/Equity of 0.85 is a leverage consideration. This is the lowest-scoring pillar and the main area of investor caution.

Taken together, the rating points to a stock with strong cash economics, notable insider support, and a balance sheet that is sound on some forensic measures but carries leverage risk. The stock's recent price movement and the 52-week range of $101 - $247.49 mean a prospective investor is evaluating a company whose valuation has changed substantially within the past year. These are educational observations, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$193.31$12.33B11.410.67.316.910%0.95$101 - $247.4929.2%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$13643.1M$2043.6M$1078.7MN/A$1310.6M$676.4M$7344.7M
FY 2024$12815.5M$2090.5M$1250.7MN/A$1466.6M$794.9M$6837.3M
FY 2023$12140.1M$1602.8M$957.0MN/A$1512.7MN/A$3409.0M

Per the SEC financials, revenue grew from $12140.1M (FY 2023) to $13643.1M (FY 2025), while net income declined from $1250.7M (FY 2024) to $1078.7M (FY 2025). Per the market data, the operating margin is 15%, the net margin is 7.9%, and the ROIC is 29.2%. The Altman Z-Score is 1.66 and the Piotroski F-Score is 8/9, both per the Roarable RQD rating. Debt rose from $3409.0M (FY 2023) to $7344.7M (FY 2025), and the Debt/Equity ratio is 0.85 per the Roarable RQD rating.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items are tagged to DVA, all with the same underlying "market action, institutional positioning, and fundamental catalysts" summary template and no article-level detail:

  • A Yahoo Finance headline, "Why DaVita (DVA) Stock Is Nosediving," is flagged YELLOW (MARKET WIRE), indicating a price decline narrative.
  • A Seeking Alpha headline references "After A 25% Drop," flagged GREEN (CATALYST), describing a buyback framing.
  • A Trefis item, a TradingView item, a Yahoo Finance item ("Stock Moves -1.01%"), and a Moomoo analyst-ratings item are flagged YELLOW (MARKET WIRE).

Risk watch items: the headlines collectively reference a price decline. Proprietary signals: none are provided in the Butterfly Supply-Chain Graph. The source data does not contain the article text, so the specific drivers of the decline are not available in source data.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data (SEC Form 4 insider, 13F institutional, or Congressional trades) is not available in source data. Note that the Roarable RQD rating references insider and institutional flow in its pillar scores, but the underlying transactions are not itemized in the provided holders section.

Open Questions

  • What specific events drove the price decline described in the news headlines, and what is the article-level evidence behind the "nosediving" characterization?
  • What is the composition and timing of the insider and institutional flows that support the 18/20 and 16/20 pillar scores?
  • What is the company's debt maturity schedule and interest coverage, given that debt rose from $3409.0M to $7344.7M over the reported periods?
  • Why does the Altman Z-Score of 1.66 coexist with a Piotroski F-Score of 8/9, and how do management and the market reconcile these signals?
  • What explains the divergence between declining net income and rising revenue across FY 2024 and FY 2025?

DVA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for DaVita Inc. (DVA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DVA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DVA Bull vs. Bear Conversation Board — What's Your Call at $187.50?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DVA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DVA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $228.11 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DVA (B+ • RQD 77/100) a Buy at $193.31?

Welcome to the DVA (DaVita Inc.) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Misc Health and Biotechnology Services. Bulls point to capital efficiency (29.2% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $160.45 (-17.0%)
Spot @ $193.31

Pump the brakes on DVA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DVA, but look at what you are paying: 11.4x trailing P/E with tightening sector spreads. Unless DaVita Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $222.31 (+15.0%)
Spot @ $193.31

DVA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DVA, the market is fixating on short-term headline noise in Misc Health and Biotechnology Services and ignoring the balance sheet and cash flow trajectory. At $193.31 (52-wk range $101.00 - $247.49), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%